Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing dobutamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Selective beta-1 adrenoceptor stimulants adverse reaction |
Causative agent (attribute) |
True |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Dobutamine adverse reaction |
Causative agent (attribute) |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Dopexamine adverse reaction |
Causative agent (attribute) |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Selective beta-1 adrenoceptor stimulants allergy |
Causative agent (attribute) |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Allergy to dobutamine |
Causative agent (attribute) |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Allergy to dopexamine |
Causative agent (attribute) |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
dobutamine 12,5 mg/mL, flacon de 20 mL d'un concentré pour perfusion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
dobutamine 50 mg/mL, ampoule de 5 mL de concentré pour perfusion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Selective beta-1 adrenoceptor agonist-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing dopexamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Dobutamine hydrochloride 12.5mg/ml infusion concentrate 20ml vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Dopexamine hydrochloride (substance) |
Is a |
True |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Dobutamine 12.5mg/mL concentrate for intravenous infusion 20mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Dopexamine (substance) |
Is a |
True |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Xamoterol (substance) |
Is a |
True |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Dobutamine (substance) |
Is a |
True |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Selective beta-1 adrenoceptor stimulants allergy |
Causative agent (attribute) |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Nebivolol hydrochloride (substance) |
Is a |
False |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Dobutamine hydrochloride |
Is a |
True |
Selective beta-1 adrenoceptor agonist |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|